EPIRUS Biopharmaceuticals, Inc. - FORM 10-K - EX-23.1 - CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM - March 9, 2012

Attached files

file filename
EXCEL - IDEA: XBRL DOCUMENT - EPIRUS Biopharmaceuticals, Inc.Financial_Report.xls
10-K - FORM 10-K - EPIRUS Biopharmaceuticals, Inc.d262669d10k.htm
EX-31.2 - CERTIFICATION OF CHIEF FINANCIAL OFFICER PURSUANT TO SECTION 302 - EPIRUS Biopharmaceuticals, Inc.d262669dex312.htm
EX-32.1 - CERTIFICATIONS OF CEO AND CFO PURSUANT SECTION 906 - EPIRUS Biopharmaceuticals, Inc.d262669dex321.htm
EX-21.1 - SUBSIDIARIES OF ZALICUS INC. - EPIRUS Biopharmaceuticals, Inc.d262669dex211.htm
EX-31.1 - CERTIFICATION OF CHIEF EXECUTIVE OFFICER PURSUANT TO SECTION 302 - EPIRUS Biopharmaceuticals, Inc.d262669dex311.htm
EX-10.41 - CONSENT & FIRST LOAN MODIFICATION AGREEMENT - EPIRUS Biopharmaceuticals, Inc.d262669dex1041.htm
EX-10.20 - SEPARATION AGREEMENT - EPIRUS Biopharmaceuticals, Inc.d262669dex1020.htm

Exhibit 23.1

Consent of Independent Registered Public Accounting Firm

We consent to the incorporation by reference in the Registration Statements (Form S-3 Nos. 333-166116 and 333-166117 and Form S-8 Nos. 333-166118, 333-131619, 333-135356 and 333-147745) of Zalicus Inc. and in the related Prospectuses of our reports dated March 9, 2012, with respect to the consolidated financial statements of Zalicus Inc., and the effectiveness of internal control over financial reporting of Zalicus Inc., included in this Annual Report (Form 10-K) for the year ended December 31, 2011.

/s/ Ernst & Young LLP

Boston, Massachusetts

March 9, 2012

Stock widget

Investing forum

EPIRUS Biopharmaceuticals, Inc. Reports

Also read